Marché des dispositifs de valve cardiaque en Amérique du Nord – Tendances et prévisions du secteur jusqu’en 2030

Analyse et perspectives du marché des dispositifs valvulaires cardiaques en Amérique du Nord

Les dispositifs de valve cardiaque sont utilisés pour traiter les valves cardiaques bloquées, et l'implantation de ces dispositifs est l'une des procédures les plus courantes. Les dispositifs de valve cardiaque structurels disponibles sur le marché comprennent les valves mécaniques, biologiques et transcathéter. Le marché nord-américain des dispositifs de valve cardiaque devrait croître régulièrement au cours de la période de prévision en raison du nombre croissant d'interventions chirurgicales de valve cardiaque à travers le monde. La croissance du marché nord-américain des dispositifs de valve cardiaque devrait être tirée par les développements des dispositifs et procédures cardiaques structurels tels que les valves aortiques, les dispositifs d'occlusion auriculaire gauche et les valves tissulaires ou biologiques. Les valves tissulaires ont déjà révolutionné le marché des dispositifs de valve cardiaque. Les chirurgies de valve cardiaque de nouvelle génération offrent des profils de patients à faible accouchement, des chirurgies plus contrôlées, une meilleure fonction de valve, une régurgitation paravalvulaire réduite, une durabilité accrue et des coûts inférieurs. Les innovations de produits des principaux acteurs du marché ont stimulé la croissance du marché en leur permettant de s'adresser à une population de patients plus large et d'obtenir de meilleurs résultats cliniques.

Data Bridge Market Research analyse que le marché des dispositifs de valves cardiaques devrait atteindre la valeur de 10 579,02 millions USD d'ici 2030, à un TCAC de 13,6 % au cours de la période de prévision. Le type de produit représente le segment de type le plus important du marché en raison de la demande rapide de dispositifs de valves cardiaques à l'échelle mondiale. Ce rapport de marché couvre également en profondeur l'analyse des prix, l'analyse des brevets et les avancées technologiques.

Définition du marché des dispositifs de valve cardiaque

Heart valves are necessary to smooth blood movement in the right direction in the body. Heart valves are responsible for constant blood flow, and maintaining blood pressure. If they don't work properly cutting off the heart causes stenosis. Heart disease generally includes several diseases that significantly affect the heart. The regulation of heart valves has increased rapidly in the last ten years as the number of patients suffering from cardiovascular diseases has increased. The market growth of heart valves is accelerated by factors such as unstable lifestyles, lifestyle diseases, increasing smoking population, aging population, and increasing quality of healthcare, and rapid development of healthcare reimbursement during the forecast period. In addition, the high cost of heart valves and the risk of infection of heart implants may be the reason that is likely to slow down the growth of the heart valve market during the above-mentioned forecast period. Growth in medical business aspects and groundwork in emerging economies is fueling growth in medical tourism, driving the heart valve device market. The need for minimally invasive procedures to treat cardiac abnormalities has greatly increased. Current applications of automation in heart valve surgery, such as Transcatheter Aortic Valve Replacement (TAVR), have given way to a growing variety of similar surgeries. Judging by the increasing proportion of the aging population, the increase in life insurance policies is also expected to contribute to the growth of the heart valve market.

 Heart Valve Devices Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Innovations in Heart Valve Devices Offer Improved Clinical Outcome

Launching new products for minimally invasive procedures will likely drive the North America heart valve devices market. Tissue valves have revolutionized the heart valve market. The next generation of heart valve surgery offers fewer delivery curves, more controlled placement, improved valve function, reduced valve regurgitation, increased durability, and reduced cost. Product innovation has boosted the growth prospects of heart valve device market players as it can treat a larger number of patients with superior clinical outcomes. Despite significant advances in recent years, structural interventional cardiology remains an emerging market with great potential.

Moreover, intelligent designs, new technologies, and biomaterials applications continue to push the boundaries of new product development, ensuring that these devices will be at the forefront of interventional product innovation for years to come. Design innovations are helping market players tap profitable growth opportunities in heart valve devices.

Thus, the growth of the North America heart valve devices market is expected to propel due to the rise in innovations in heart valve devices.

• Rising number of various heart diseases

Heart attacks and strokes are usually acute events and are primarily caused by a blockage that blocks blood flow to the heart or brain. During the first year of the COVID-19 pandemic, heart disease and stroke deaths increased by 5.8% and 6.8%, respectively. However, the age-associated increases were 1.6% and 1.7% for heart disease and stroke, respectively. The most common cause is the build-up of fatty deposits in the lining of the blood vessels that supply the heart or brain. A stroke can be caused by bleeding or blood clots in a blood vessel in the brain. This trend suggests that the incidence of cardiovascular disease may increase dramatically due to population growth and aging.

Furthermore, High diabetes and blood pressure, high blood cholesterol, and smoking are key risk factors for heart disease. About half of people in the United States (47%) have at least one of these three risk factors. Other medical conditions and lifestyle choices can also put people at a higher risk for heart disease, including unhealthy diet, physical inactivity, and excessive alcohol use.

Moreover, the rising number of heart diseases is expected to act as a driver for the North America heart valve devices market.

Opportunity

• Increasing Awareness of Prosthetic Devices

A prosthesis is a device designed to replace a missing body part or to improve the function of a body part. Prosthetic heart valves are increasingly used in cases of abnormalities of the natural valves that require intervention. Generally, they can be divided into mechanical heart valves, biological valves, and allogeneic grafts. The goal of artificial valves is to act hemodynamically like a natural valve with minimal side effects. Cardiovascular prostheses devices have been developed to replace damaged heart tissue. These medical devices are designed to mimic the function of normal cardiovascular organs. Artificial hearts allow heart surgeons to increase the treatment of heart blocks.

Moreover, the prevalence of prosthetic valves ranges from 0.2 per 1,000 in people years of age or younger to 5.3 in people years of age or younger.

Thus the increasing awareness about prosthetic devices acts as an opportunity for the market's growth.

Restraint/Challenge

• Expensive Production Cost of Equipment

The number of patients treated for aortic valve disease in the United States is growing quickly. Transcatheter aortic valve replacement (TAVR) replaces surgical aortic valve replacement (SAVR) and medical treatment (M.T.). The economic consequences of these trends are unknown. Therefore, the total cost of TAVR is higher than SAVR and much more expensive than M.T. alone. TAVR costs have decreased over time, while SAVR and M.T. costs have remained the same.

In addition, the high surgical cost of TAVI is mainly due to the high cost of the production. However, due to the shorter hospital stay, the cost of non-surgical TAVI is lower compared to AVR. The cost of the TAVI implant kit alone (valve, balloon, sheath) is $32,500, while the surgical valve only costs about $5,000, just like in Switzerland, the TAVI implant set costs about 32,000 francs (around of $35,000), while the cost of a biosurgical prosthesis is about 3,000 Swiss francs (about US$3,300). Depending on comorbidities and complications, reimbursement in the United States is between $ 0,000 and $ 5,000, TAVI in Switzerland is about 72,000 francs ($78,000), and AVR is about 3,000 francs ($ 7,000), which means a financial loss for the hospital.

Thus, the rising production cost of equipment may hamper the market's growth.

Recent Developments

• In September 2023, Abbott released data from five late-stage presentations showing the benefits of its minimally invasive devices in treating people with various structural heart diseases. The data includes findings that support the value of MitraClip™. It is the world's first and leading transcatheter edge-to-edge repair (TEER) to treat leaky valves in people with mitral regurgitation (MR). New data on Abbott's structural heart therapies were presented at the Cardiovascular Research Foundation's 34th Annual Transcatheter Cardiovascular Therapy (TCT) Scientific Symposium in Boston. This has helped the company to increase its business position in the market.
• In September 2020, Boston Scientific Corporation announced that it had introduced a controlled launch of the ACURATE neo2™ aortic valve system in Europe. This next-generation transcatheter aortic valve implantation (TAVI) technology is a new platform designed with multiple features to improve the clinical performance of the original ACURATE new platform. Compared to the previous generation, the ACURATE neo2 valve system has an expanded indication for patients with aortic stenosis. This has helped the company to gain its product portfolio.

Heart Valve Devices Market Scope

The heart valve devices market is segmented into product type, treatment, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

BY PRODUCT TYPE

• Mechanical Heart Valves
• Biological Heart Valve
• Transcatheter Valves

On the basis of product type, the heart valve devices market is segmented into mechanical heart valve, biological heart valve and transcatheter valve.

BY TREATMENT

• OPEN SURGERY
• MINIMALLY INVASIVE SURGERY

On the basis of treatment, the heart valve devices market is segmented into open surgery and minimal invasive surgery.

 BY END USER

• HOSPITAL & CLINICS
•  AMBULATORY SURGICAL CENTERS
• CARDIAC CENTERS
• RESEARCH CENTERS
• OTHERS

Sur la base de l'utilisateur final, le marché des dispositifs de valve cardiaque est segmenté en hôpitaux et cliniques, centres de chirurgie ambulatoire, centres cardiaques, centres de recherche et autres.

PAR CANAL DE DISTRIBUTION

• APPEL D'OFFRES DIRECT
• DISTRIBUTEURS TIERS

Sur la base du canal de distribution, le marché des dispositifs de valve cardiaque est segmenté en appels d'offres directs et distributeurs tiers.

Analyse/perspectives régionales du marché des dispositifs de valve cardiaque en Amérique du Nord

Le marché des dispositifs valvulaires cardiaques est analysé et des informations sur la taille du marché sont fournies : type de produit, traitement, utilisateur final et canal de distribution.

Les pays couverts par ce rapport de marché sont les États-Unis, le Canada et le Mexique.

L'Amérique du Nord domine le marché en raison de l'augmentation des investissements en R&D. Les États-Unis dominent la région Amérique du Nord en raison de la forte présence d'acteurs clés.

La section du rapport sur les pays fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que les nouvelles ventes, les ventes de remplacement, la démographie des pays, les actes réglementaires et les tarifs d'importation et d'exportation sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques nord-américaines et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, ainsi que l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des dispositifs de valve cardiaque

Le paysage concurrentiel du marché des dispositifs de valve cardiaque fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais de produits, les approbations de produits, les brevets, la largeur et la portée du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché des dispositifs de valve cardiaque.

Certains des principaux acteurs opérant sur le marché des dispositifs de valve cardiaque sont Abbott, Boston Scientific Corporation ou ses filiales, Artivion, Inc., Edwards Lifesciences Corporation, Medtronic, NeoVasc, Micro Interventional Devices Incorporated, XELTIS, TTK, Meril Life Sciences Pvt. Ltd, Foldax, Inc., Venus Medtech (Hangzhou) Inc., Colibri Heart Valve, entre autres.

SKU-69459